DexCom (NASDAQ:DXCM) Trading Down 3.1%

DexCom, Inc. (NASDAQ:DXCM) dropped 3.1% on Thursday . The company traded as low as $475.00 and last traded at $475.00. Approximately 1,974 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 775,246 shares. The stock had previously closed at $490.38.

DXCM has been the topic of a number of research analyst reports. Robert W. Baird upped their target price on DexCom from $520.00 to $625.00 and gave the stock an “outperform” rating in a research note on Friday, October 29th. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating and set a $580.00 target price on the stock in a research note on Friday, January 7th. Raymond James increased their price objective on DexCom from $515.00 to $618.00 and gave the company an “outperform” rating in a research report on Monday, November 1st. Citigroup increased their price objective on DexCom from $630.00 to $660.00 and gave the company a “buy” rating in a research report on Friday, October 29th. Finally, SVB Leerink increased their price objective on DexCom from $500.00 to $715.00 and gave the company an “outperform” rating in a research report on Friday, October 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, DexCom has an average rating of “Buy” and a consensus target price of $582.50.

The firm has a 50-day moving average of $563.89 and a 200-day moving average of $533.74. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.50 and a current ratio of 4.98. The firm has a market capitalization of $43.36 billion, a P/E ratio of 85.53 and a beta of 0.78.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 28th. The medical device company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.27. DexCom had a return on equity of 14.65% and a net margin of 22.82%. The business had revenue of $650.20 million for the quarter, compared to analyst estimates of $617.07 million. During the same period last year, the company earned $0.94 EPS. DexCom’s revenue for the quarter was up 29.8% compared to the same quarter last year. Equities analysts anticipate that DexCom, Inc. will post 2.8 EPS for the current fiscal year.

In other DexCom news, CFO Jereme M. Sylvain sold 600 shares of the stock in a transaction that occurred on Monday, December 6th. The stock was sold at an average price of $517.59, for a total value of $310,554.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 3,000 shares of the stock in a transaction that occurred on Monday, November 15th. The stock was sold at an average price of $647.84, for a total value of $1,943,520.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,420 shares of company stock valued at $8,597,547. Company insiders own 0.52% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DXCM. MUFG Americas Holdings Corp purchased a new position in shares of DexCom in the 3rd quarter valued at approximately $36,000. Jacobi Capital Management LLC lifted its stake in shares of DexCom by 31.8% in the 2nd quarter. Jacobi Capital Management LLC now owns 87 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 21 shares during the period. Farmers & Merchants Investments Inc. lifted its stake in shares of DexCom by 45.1% in the 3rd quarter. Farmers & Merchants Investments Inc. now owns 74 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 23 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of DexCom in the 2nd quarter valued at approximately $43,000. Finally, Logan Capital Management Inc. lifted its stake in shares of DexCom by 77.3% in the 3rd quarter. Logan Capital Management Inc. now owns 78 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 34 shares during the period. Institutional investors own 94.26% of the company’s stock.

DexCom Company Profile (NASDAQ:DXCM)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.

Recommended Story: No Load Funds

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.